Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Oxford Instruments FY revenue exceeds £500m for first time

(Sharecast News) - Oxford Instruments reported adjusted revenue and operating profit growth in the 12 months ended 31 March, driven by "good" momentum and "robust" demand. Oxford Instruments said FY revenues had grown 6.5% to £500.6m, exceeding £500.0m for the first time in company history, while operating profits were up 10.8% at £82.2m.

Pre-tax profits were 8.3% higher at £83.4m and basic earnings per share were up 3.1% at 112.4p. Operating profit margins dipped 70 basis points to 16.4%.

The FTSE 250-listed firm said it had delivered "good growth" in semiconductor and materials analysis, offsetting continued weakness in healthcare and life science, and also pointed to a "strong performance" across North America, Asia and Europe.

Oxford Instruments highlighted that "robust demand" and its resulting orderbook had provided it with "good visibility" for the year ahead.

Oxford Instruments also noted that it has entered into a binding agreement to sell its quantum business for £60.0m. It said the sale of NanoScience would accelerate progress to deliver its medium-term margin targets and enable it to launch a new £50.0m share buyback programme.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.